Skip to content
Peptide research

Tirzepatide

Also known as Mounjaro · Zepbound
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
FDA-approved

A dual GIP/GLP-1 receptor agonist used for weight loss and metabolic health. Human evidence is strong: trials show superior weight loss, glycemic control, and heart failure benefit, with softer data on cardiovascular risk. GI side effects are common, and a boxed warning for thyroid tumors in animal studies rules it out for anyone with a history of medullary thyroid cancer or MEN 2. It is FDA-approved, sold as a regulated pharmaceutical, not research-grade.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Mounjaro and Zepbound (tirzepatide) is a first-in-class dual-action injectable medication that mimics two natural gut hormones — GIP and GLP-1 — that your body releases after eating to signal fullness and regulate blood sugar. It is FDA-approved as Mounjaro for type 2 diabetes, Zepbound for chronic weight management, and also for obstructive sleep apnea related to obesity. Dosed once weekly, it represents one of the most effective weight loss medications ever developed.

How it works in the body

A dual GIP and GLP-1 receptor agonist. GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 are incretin hormones released after eating. By activating both receptors simultaneously, tirzepatide produces stronger insulin secretion, greater appetite suppression, and more weight loss than either pathway alone.

Research overview

Tirzepatide works by simultaneously activating both the GIP and GLP-1 receptors, triggering multiple mechanisms: boosting insulin release when blood sugar is high, suppressing the hormone glucagon, slowing stomach emptying so you feel full longer, and reducing appetite through direct effects on brain hunger centers. Its built-in fatty acid chain binds to albumin in the blood, allowing it to last a full week per dose. Clinical trials showed tirzepatide improves insulin sensitivity beyond what single-target GLP-1 drugs like semaglutide achieve. In the SURMOUNT trials for weight management, participants lost up to 22.5% of body weight on the highest dose. The dual mechanism is thought to explain its superior efficacy compared to GLP-1-only drugs, and SURMOUNT-5 has published head-to-head weight-loss results.

Who researches Tirzepatide?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People exploring sleep quality improvement

    Researched for effects on sleep architecture, circadian rhythm, or sleep quality.

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

Important considerations for

  • Those with Personal/family history of medullary thyroid carcinoma

    Absolute

    Same thyroid C-cell tumor risk as other incretin-based therapies. Contraindicated in MTC/MEN2.

  • Those with History of pancreatitis

    High

    Monitor closely. Discontinue if pancreatitis suspected.

  • Those with Severe gastroparesis

    High

    Dual GIP/GLP-1 action significantly slows gastric emptying.

  • Those who are pregnant or breastfeeding

    Absolute

    Discontinue at least 2 months before planned conception.

Safety & interactions

Do not use if

  • Personal/family history of medullary thyroid carcinoma

    Absolute

    Same thyroid C-cell tumor risk as other incretin-based therapies. Contraindicated in MTC/MEN2.

  • History of pancreatitis

    High

    Monitor closely. Discontinue if pancreatitis suspected.

  • Severe gastroparesis

    High

    Dual GIP/GLP-1 action significantly slows gastric emptying.

General cautions

  • Pregnancy

    Absolute

    Do not use during pregnancy. MHRA guidance recommends stopping tirzepatide at least 1 month before a planned pregnancy.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • GI side effects: nausea (13-24%), diarrhea (13-21%), vomiting (6-14%)

    High

    FDA Mounjaro/Zepbound prescribing information (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide); PMID 39555826 (SUMMIT)

  • Boxed warning: thyroid C-cell tumors in animal studies

    Moderate

    FDA Mounjaro/Zepbound prescribing information, Boxed Warning (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)

  • Pancreatitis risk (rare)

    Low

    FDA Mounjaro/Zepbound prescribing information, Warnings and Precautions (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)

  • Gallbladder disease

    Moderate

    FDA Zepbound prescribing information, Warnings and Precautions (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)

  • Potential for hypoglycemia when combined with insulin or sulfonylureas

    Moderate

    FDA Mounjaro prescribing information, Warnings and Precautions / Drug Interactions (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)

  • Contraindicated: personal/family history of medullary thyroid carcinoma or MEN 2

    High

    FDA Mounjaro/Zepbound prescribing information, Contraindications (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)

Interaction summary(8)

Rated by direction with this peptide

  • Insulin and sulfonylureas (e.g. glimepiride, glipizide)

    CautionHigh

    Adding tirzepatide to insulin or a sulfonylurea substantially raises the rate of clinically significant hypoglycemia; the label advises considering a dose reduction of the insulin or secretagogue when starting.

    FDA Mounjaro prescribing information, Warnings and Precautions 5.4 / Drug Interactions (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)

  • Oral hormonal contraceptives

    CautionHigh

    Tirzepatide delays gastric emptying and reduces oral contraceptive exposure, and the label directs patients to switch to a non-oral method or add a barrier method for 4 weeks after initiation and after each dose escalation — a real, PK-demonstrated interaction with pregnancy-risk consequences.

    FDA Mounjaro/Zepbound prescribing information, Drug Interactions 7.1 (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)

  • Other GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and DPP-4 inhibitors

    CautionModerate

    Concurrent use is redundant on the same incretin axis with no demonstrated added benefit and additive GI toxicity; tirzepatide has not been studied with other GLP-1 RAs and co-prescription is not recommended.

    FDA Mounjaro prescribing information, Limitations of Use / Clinical Pharmacology (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)

  • Anesthesia and procedural sedation (elective surgery, endoscopy)

    CautionModerate

    Delayed gastric emptying can leave retained gastric contents despite standard fasting, raising pulmonary aspiration risk; anesthesiology consensus guidance recommends holding weekly GLP-1/GIP agonists before elective procedures and treating patients as full-stomach if symptomatic.

    American Society of Anesthesiologists consensus-based guidance on preoperative management of GLP-1 receptor agonists (2023); FDA label Warnings and Precautions (pulmonary aspiration)

  • Narrow-therapeutic-index oral drugs (warfarin, levothyroxine, digoxin, antiepileptics)

    CautionLow

    Slowed gastric emptying can alter the rate and, less predictably, extent of oral absorption, so the label advises monitoring where small exposure changes matter clinically — mechanism-based rather than demonstrated for most individual agents.

    FDA Mounjaro prescribing information, Drug Interactions 7.2 (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)

  • Diuretics, ACE inhibitors/ARBs and NSAIDs

    CautionModerate

    During tirzepatide-related vomiting or diarrhea, volume depletion on top of these agents can precipitate acute kidney injury or worsen existing renal impairment — an explicitly labeled warning, with reported post-marketing AKI cases.

    FDA Mounjaro prescribing information, Warnings and Precautions (acute kidney injury) (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)

  • SGLT2 inhibitors (empagliflozin, dapagliflozin)

    SynergisticLow

    Complementary mechanisms give additive HbA1c, weight and cardiorenal benefit and the combination is widely used, but both promote volume loss, so hydration and renal function warrant attention during GI illness.

    FDA Mounjaro prescribing information (concomitant use in SURPASS program); ADA Standards of Care

  • Metformin

    NeutralLow

    No clinically relevant pharmacokinetic interaction; metformin was background therapy in most SURPASS trials, though overlapping GI effects can compound nausea and diarrhea during dose escalation.

    FDA Mounjaro prescribing information, Clinical Pharmacology 12.3 (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)

Known risks(6)

  • GI side effects: nausea (13-24%), diarrhea (13-21%), vomiting (6-14%)

  • Boxed warning: thyroid C-cell tumors in animal studies

  • Pancreatitis risk (rare)

  • Gallbladder disease

  • Potential for hypoglycemia when combined with insulin or sulfonylureas

  • Contraindicated: personal/family history of medullary thyroid carcinoma or MEN 2

Drug interactions(4)

  • Semaglutide

    Both act on GLP-1 receptors. Combining increases GI side effects and hypoglycemia risk.

  • Insulin

    Increased hypoglycemia risk. Reduce insulin dose when starting tirzepatide.

  • Sulfonylureas

    Hypoglycemia risk. Consider dose reduction.

  • Oral contraceptives

    Slowed gastric emptying may reduce absorption. Use a barrier method for 4 weeks after starting treatment and after each increase.

Research & benefits

Evidence base

Evidence Level
Level 1 — Strong
Total Studies
600
Human Participants
35000

600+ PubMed studies. 35,000+ participants across SURPASS (T2DM), SURMOUNT (obesity), SUMMIT (HFpEF), SYNERGY-NASH, SURMOUNT-OSA programs. SURPASS-CVOT alone had 13,000+ patients over 4+ years.

Researched for(8)

Rated by confidence in the evidence

  • Superior weight loss

    High

    Multiple large RCTs showed 15-21% weight loss, exceeding semaglutide in a head-to-head trial.

    PMID 35658024 (SURMOUNT-1, NEJM 2022); PMID 37385275 (SURMOUNT-2, Lancet 2023); PMID 34170647 (SURPASS-2, NEJM 2021)

  • Glycemic control

    High

    Multiple phase 3 trials showed HbA1c reductions of 2-2.6 points, beating semaglutide and insulin.

    PMID 34170647 (SURPASS-2, NEJM 2021); FDA Mounjaro prescribing information (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)

  • T2D prevention

    High

    Single large trial found a 93% reduction in diabetes progression among adults with prediabetes.

    PMID 39536238 (Jastreboff et al., NEJM 2025 — SURMOUNT-1 3-year prediabetes results)

  • Heart failure (HFpEF)

    High

    Dedicated RCT in obesity-related HFpEF found 38% fewer cardiovascular deaths or worsening heart failure events.

    PMID 39555826 (Packer et al., NEJM 2025 — SUMMIT)

  • CV risk reduction

    Medium

    Large outcomes trial showed noninferiority to another GLP-1 drug, not superiority, for cardiovascular events.

    PMID 41406444 (Nicholls et al., NEJM 2025 — SURPASS-CVOT); PMID 39555826 (SUMMIT)

  • MASH/NASH resolution

    Medium

    One 52-week trial found MASH resolution in up to 62% versus 10% with placebo.

    PMID 38856224 (Loomba et al., NEJM 2024 — SYNERGY-NASH)

  • Sleep apnea

    High

    Two large RCTs cut AHI by 25-29 events per hour in obesity-related sleep apnea, FDA-approved.

    PMID 38912654 (Malhotra et al., NEJM 2024 — SURMOUNT-OSA)

  • Cardiometabolic

    High

    Consistent improvements in blood pressure, lipids, and inflammation seen as secondary trial endpoints.

    PMID 35658024 (SURMOUNT-1); PMID 38912654 (SURMOUNT-OSA); PMID 34170647 (SURPASS-2)

Benefits(8)

  • Superior weight loss

  • Glycemic control

  • T2D prevention

  • Heart failure (HFpEF)

  • CV risk reduction

  • MASH/NASH resolution

  • Sleep apnea

  • Cardiometabolic

Key studies(5)

  1. Jastreboff AM et al.

    NEJM

    2022

    22.5% weight loss at 15mg/72wk. 63% achieved ≥20% loss.

  2. Frias JP et al.

    NEJM

    2021

    All doses superior to semaglutide 1mg for HbA1c and weight

  3. Aronne LJ et al.

    NEJM

    2025

    20.2% vs 13.7% weight loss head-to-head

  4. Packer M et al.

    NEJM

    2025

    38% reduction CV death/worsening HF (HR 0.62)

  5. Loomba R et al.

    NEJM

    2024

    62% MASH resolution at 15mg, liver fat -57%

What research suggests over time

  • Weeks 2-4

    SURMOUNT-1 (NEJM 2022)

    Appetite suppression begins; ~2-3% body weight loss after the first month of titration.

  • Months 2-3

    SURMOUNT-1 / SURPASS-2

    ~7-10% weight loss as treatment escalates; A1c reductions of 1.5-2.0% in T2DM.

  • Long-term

    Phase 3 RCT

    Mean 22.5% weight loss at 72 weeks (highest-dose arm). SURMOUNT-4 showed 82% of users regained >25% within 1 year of stopping.

Prescribing labels

FDA-Approved Labels

This page does not list doses. Each product below has an FDA label with its prescribing information.

Protocol
Mounjaro (tirzepatide)
Notes
Dosing is set by your prescriber and the FDA label.
Protocol
Zepbound (tirzepatide)
Notes
Dosing is set by your prescriber and the FDA label.

Monitoring & labs

Baseline before starting, then per marker schedule during protocol.

Baseline labs(7)

  • Complete Blood Count (CBC)

    Optimal All markers within mid-range

    Establishes baseline for detecting hematological changes.

    Lab normal Standard reference ranges

  • Comprehensive Metabolic Panel (CMP)

    Optimal Liver enzymes <25, glucose 75–90, eGFR >90

    Liver and kidney function baseline.

    Lab normal Standard reference ranges

  • Fasting glucose + HbA1c

    Optimal 75–90 mg/dL

    Baseline metabolic markers — critical for tracking glucose regulation changes.

    Lab normal 65–99 mg/dL

  • Lipid panel

    Optimal ApoB <80, TG <80, HDL >55

    Cholesterol and triglyceride baseline for tracking cardiovascular metabolic effects.

    Lab normal TC <200, LDL <100, HDL >40, TG <150

  • Thyroid panel (TSH, free T3/T4)

    Optimal TSH 1.0–2.0; Free T3 upper third of range

    Thyroid function can be affected by metabolic peptides.

    Lab normal TSH 0.4–4.5

  • Amylase + Lipase

    Optimal Both within mid-range

    Baseline pancreatic markers — this peptide carries a documented pancreatitis risk.

    Lab normal Standard ranges

  • Calcitonin

    Optimal Under 5 pg/mL

    Baseline thyroid C-cell marker — this peptide carries a thyroid tumor risk warning.

    Lab normal Under 10 pg/mL (men)

Ongoing tracking(5)

  • Fasting glucose + HbA1c

    Every 4-8 weeksOptimal 75–90 mg/dL

    Track glucose regulation changes during protocol.

    Lab normal 65–99 mg/dL

  • Lipid panel

    Every 8-12 weeksOptimal ApoB <80, TG <80, HDL >55

    Monitor cholesterol and triglyceride response.

    Lab normal TC <200, LDL <100, HDL >40, TG <150

  • Liver enzymes (ALT/AST)

    Every 8 weeksOptimal ALT & AST under 25 U/L

    Hepatic function monitoring during metabolic modulation.

    Lab normal ALT 7–56, AST 10–40 U/L

  • Amylase + Lipase

    Every 8-12 weeksOptimal Both within mid-range

    Pancreatic enzyme monitoring — pancreatitis risk.

    Lab normal Standard ranges

  • Calcitonin

    Every 12 weeksOptimal Under 5 pg/mL

    Thyroid C-cell monitoring — MTC risk.

    Lab normal Under 10 pg/mL (men)

Retest schedule(6)

  1. Baseline

    critical

    Before starting

    Full baseline + thyroid panel, lipase, amylase, HbA1c, lipid panel.

  2. Early follow-up

    critical

    Week 4

    Recheck lipase, amylase, glucose. Most early-protocol concerns surface here.

  3. Second check

    critical

    Week 8

    Recheck metabolic markers and GI tolerance.

  4. Mid-protocol

    critical

    Week 12

    Comprehensive retest. Track HbA1c, weight, lipids, thyroid.

  5. Ongoing

    standard

    Every 12 weeks

    Sustained metabolic monitoring during chronic use.

  6. Post-protocol

    standard

    4-6 weeks after stopping

    Track for weight regain and metabolic rebound.

When to stop and reassess(7)

  • ALT or AST

    stop

    Above 2× upper limit of normal (>~80 U/L)

    Stop protocol and consult a provider — possible drug-induced liver injury.

  • eGFR

    stop

    Drop of >15 mL/min/1.73m² from baseline, or below 60

    Stop protocol and consult a provider — possible kidney function decline.

  • Symptoms

    stop

    New severe symptoms correlating with lab changes

    Stop protocol and seek medical evaluation immediately.

  • Lipase or amylase

    stop

    Above 3× upper limit of normal

    Stop protocol and seek urgent medical evaluation — possible pancreatitis.

  • Calcitonin

    consult

    Above 10 pg/mL or rising trend

    Consult an endocrinologist — possible thyroid C-cell stimulation.

  • Heart rate

    consult

    Sustained >100 bpm or new palpitations

    Consult a provider — GLP-1 agonists can affect cardiac rhythm.

  • Lipase

    stop

    Above 3× upper limit of normal

    Stop protocol and seek urgent medical evaluation — pancreatitis risk documented.

Lab monitoring helps track your body's response to Tirzepatide. Any unexplained changes should prompt discussion with your prescribing provider.

Regulation & availability

Why researchers look at it

SURMOUNT trial participants lost up to 22.5% of body weight — surpassing semaglutide in head-to-head comparisons — making it the most effective weight loss medication in clinical history. Across 35,000+ participants (SURPASS, SURMOUNT, SUMMIT), benefits extend well beyond weight: reduced heart failure hospitalizations, improved liver fat, and resolution of sleep apnea. SURPASS-CVOT has reported cardiovascular noninferiority to dulaglutide; superiority for its primary cardiovascular endpoint was not established.

Estimated cost
Self-pay $299-699/mo for Zepbound by dose (LillyDirect, checked 21 Oct 2026); $90-399/mo compounded through telehealth; some providers add a membership fee
FDA status
FDA-approved: Mounjaro (T2DM May 2022), Zepbound (obesity November 2023, OSA December 2024). Zepbound KwikPen launched February 2026. Shortage-related compounding enforcement discretion ended in 2025; enforcement continues. According to Lilly, Zepbound was the most prescribed weight-management drug in the U.S. in 2025.
WADA status
Not explicitly banned. Under monitoring similar to other incretin therapies.
Prescribability
FDA-approved Rx. Mounjaro (T2DM, May 2022), Zepbound (obesity Nov 2023, OSA Dec 2024). Compounding largely ended after FDA's shortage-related enforcement discretion ended in early 2025.
Availability
Rx only. Mounjaro and Zepbound are available at pharmacies, with LillyDirect self-pay options. Zepbound KwikPen was approved January 20, 2026 and launched February 23. Shortage-related compounding discretion ended in March 2025. Medicare GLP-1 Bridge access to Zepbound KwikPen began July 1, 2026 for eligible beneficiaries.

International status

  • EU

    EMA-approved (Mounjaro)

  • UK

    MHRA-approved

  • US

    FDA-approved (Mounjaro, Zepbound)

  • Japan

    PMDA-approved

  • Canada

    Health Canada-approved

  • Australia

    TGA-approved

Regulatory timeline(5)

  1. 2022-05
    Mounjaro FDA approvalT2DM indication
  2. 2023-11
    Zepbound FDA approvalWeight management indication
  3. 2024-10
    Shortage resolvedFDA ended tirzepatide shortage. Compounding enforcement began.
  4. 2024-12
    Zepbound OSA approvalModerate-to-severe obstructive sleep apnea
  5. 2026-01-20
    KwikPen approvedMulti-dose pen for Zepbound. Self-pay from $299/mo via LillyDirect.

Sources & FAQs

Research sources(5)

Frequently asked questions(4)

How does it differ from semaglutide?

Dual GIP/GLP-1 vs GLP-1 only. Greater weight loss (20.2% vs 13.7% head-to-head) and superior HbA1c reduction.

Common side effects?

GI: nausea 13-24%, diarrhea 13-21%, vomiting 6-14%. Mild-moderate, diminish over time. Discontinuation 4-10%.

Compounded tirzepatide in 2026?

Largely unavailable. Shortage resolved Oct 2024. FDA enforcement active. Brand Mounjaro/Zepbound or LillyDirect self-pay vials.

CV benefits beyond weight loss?

Yes: 38% HF reduction (SUMMIT), 16% all-cause mortality reduction (SURPASS-CVOT), significant BP and triglyceride improvements.